(E)-3,5-diphenylpent-2-en-4-ynoic acid methyl ester | 151665-70-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3,5-diphenylpent-2-en-4-ynoic acid methyl ester
• 英文别名: trans-3,5-Diphenyl-pent-2-en-4-in-saeure-methylester；methyl (E)-3,5-diphenylpent-2-en-4-ynoate；Methyl (E)-3,5-diphenylpent-2-en-4-ynoate
• CAS: 151665-70-2
• 化学式: C₁₈H₁₄O₂
• 分子量: 262.308
• InChiKey: SZWVMVLXOJCQGR-VKAVYKQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-3,5-diphenylpent-2-en-4-ynoic acid methyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 trans-3,5-Diphenyl-pent-2-en-4-in-saeure
  参考文献：
  名称：

  N-acryloylpiperazine derivatives, their preparation and their use as PAF

  摘要：

  式(I)的化合物：其中R.sup.1和R.sup.2分别为--R.sup.5，--CH.dbd.CH--R.sup.5或--C.tbd.C--R.sup.5，其中R.sup.5是可选择取代的芳基或芳香杂环基；R.sup.3是氢，烷基，氰基或--R.sup.5；X是氧或硫；A是1,4-哌嗪-1,4-二基或1,4-同源哌嗪-1,4-二基；B'是烷基，羰基，硫代羰基，砜基或磺酰基；R.sup.4是可选择取代的苯基和其药用盐具有有价值的PAF拮抗活性，可以通过将含有分子中哌嗪或同源哌嗪部分的化合物与含有分子的其他部分的化合物反应来制备。

  公开号：

  US05192766A1
• 作为产物：
  描述：

  苯丙炔酸甲酯 、 苯乙炔 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(I) bromide 作用下， 以 水 为溶剂， 反应 42.0h， 以75%的产率得到(E)-3,5-diphenylpent-2-en-4-ynoic acid methyl ester
  参考文献：
  名称：

  Facile and selective copper–palladium catalyzed addition of terminal alkynes to activated alkynes in water

  摘要：

  The combination of palladium and copper catalyzes the addition of terminal alkynes to electron-deficient alkynes selectively and effectively in water without the competition of terminal alkynes' homo-coupling. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.02.038

文献信息

• Iridium Complex-Catalyzed Cross-Coupling Reaction of Terminal Alkynes with Internal Alkynesvia CH Activation of Terminal Alkynes
  作者：Tomotaka Hirabayashi、Satoshi Sakaguchi、Yasutaka Ishii

  DOI：10.1002/adsc.200404359

  日期：2005.5

  complex to produce a 1 : 1 adduct in high regio- and stereoselectivities. This reaction was extended to various combinations of terminal alkynes with internal alkynes such as alkynyl esters and alkynyl aldehydes. The selectivity of the reaction was found to markedly depend on the ligands used. When dppe was used as a ligand, the 1 : 2 cross-cyclotrimerization reaction took place to form substituted benzene

  铱络合物促进富电子的末端炔与缺电子的内部炔的二聚，从而在高区域选择性和立体选择性下产生1：1加合物。该反应扩展到末端炔烃与内部炔烃如炔基酯和炔基醛的各种组合。发现反应的选择性显着取决于所用的配体。当dppe用作配体时，发生1：2交叉环三聚反应以形成取代的苯衍生物。根据标记实验，提出了一条合理的反应路径。该反应提供了生产复杂的炔烃的方法，该方法难以通过常规方法制备。
• Method of treating a PAF-mediated pathology or for treating or
  申请人：Sankko Company, Limited

  公开号：US05559109A1

  公开（公告）日：1996-09-24

  A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.

  通过给予有效量的PAF拮抗剂的方法来治疗PAF介导的病理或治疗或预防银屑病、肾炎、哮喘、炎症或休克，其中所述PAF拮抗剂的化学式为##STR1##其中R.sup.1和R.sup.2分别是--R.sup.5，--CH.dbd.CH--R.sup.5或--C.tbd.C--R.sup.5; R.sup.5是未取代或取代的C.sub.6-C.sub.14碳环芳基或含有5至14个环原子的芳香杂环中的一种，其中从1至5个是从氮、氧和硫组成的杂原子，所述杂环基未取代或取代; R.sup.3是氢、C.sub.1-C.sub.6烷基、氰基或--R.sup.5; X是氧或硫; A是1,4-哌嗪-1,4-二基或1,4-同哌嗪-1,4-二基; B是C.sub.1-C.sub.6烷基、羰基、硫代羰基、亚砜基或磺酰基; R.sup.4是未取代或取代的苯基。
• N-acryloylpiperazine compounds
  申请人：Sankyo Company, Limited

  公开号：US05556852A1

  公开（公告）日：1996-09-17

  Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl: and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity.

  化学式为(I)的化合物：其中R.sup.1和R.sup.2分别为--R.sup.5，--CH.dbd.CH--R.sup.5或--C.tbd.C--R.sup.5，其中R.sup.5为可选择取代的芳基或芳香族杂环基；R.sup.3为氢，烷基，氰基或--R.sup.5；X为氧或硫；A为1,4-哌嗪-1,4-二基或1,4-同源哌嗪-1,4-二基；B'为烷基，羰基，硫代羰基，亚砜基或磺酰基；R.sup.4为可选择取代的苯基及其药物学上可接受的盐具有有价值的PAF拮抗活性。
• N-acryloylpiperazine derivatives, their preparation and their use of PAF
  申请人：Sankyo Company, Limited

  公开号：US05369106A1

  公开（公告）日：1994-11-29

  Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the homopiperazine part of the molecule with a compound containing the other part of the molecule.

  化合物的式子(I)：##STR1## 其中R.sup.1和R.sup.2分别是--R.sup.5, --CH.dbd.CH--R.sup.5或--C.tbd.C--R.sup.5，其中R.sup.5是可选择取代芳基或芳香族杂环基；R.sup.3是氢，烷基，氰基或--R.sup.5；X是氧或硫；A是1,4-同型吡嗪-1,4-二基；B'是烷基，羰基，硫代羰基，亚砜基或磺酰基；R.sup.4是可选择取代的苯基和药学上可接受的盐，具有有价值的PAF拮抗剂活性，并且可以通过将含有分子中同型吡嗪环部分的化合物与含有分子中其他部分的化合物反应来制备。
• Facile and selective copper–palladium catalyzed addition of terminal alkynes to activated alkynes in water
  作者：Liang Chen、Chao-Jun Li

  DOI：10.1016/j.tetlet.2004.02.038

  日期：2004.3

  The combination of palladium and copper catalyzes the addition of terminal alkynes to electron-deficient alkynes selectively and effectively in water without the competition of terminal alkynes' homo-coupling. (C) 2004 Elsevier Ltd. All rights reserved.